Hepion Pharmaceuticals, Inc.
HEPAOTCHealthcare● Active
$0.06
$-0.02(-23.75%)
Market Cap$710266
P/E Ratio—
52W High$0.25
52W Low$0.033
Hepion Pharmaceuticals, Inc. (HEPA) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
HEPA · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: Apr 6, 2026EPS Actual
-$0.06
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
Apr 6, 2026
After Market Close
🔥 5-Quarter EPS Beat Streak
HEPA reports quarterly as a OTC-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Sep 2, 2026 | -$200.00 | — | — | — | — | — |
| ◌ Q3 FY2026 | Sep 2, 2026 | -$190.00 | — | — | — | — | — |
| — Q2 FY2026 | Apr 6, 2026 | — | -$0.06 | — | — | — | — |
| — Q4 FY2025 | Nov 12, 2025 | — | -$0.04 | — | — | — | — |
| — Q3 FY2025 | Aug 15, 2025 | — | -$0.09 | — | — | — | — |
| — Q2 FY2025 | May 19, 2025 | — | -$2.15 | — | — | — | — |
| ▲ Q2 FY2025 | Apr 8, 2025 | -$98.50 | -$11.12 | +88.7% | — | — | — |
| ▲ Q4 FY2024 | Nov 14, 2024 | -$95.00 | -$36.00 | +62.1% | — | — | — |
Q3 FY2026
Sep 2, 2026
EPS Actual
—
EPS Est.
-$200.00
EPS Surpr.
—
Revenue
—
Q3 FY2026
Sep 2, 2026
EPS Actual
—
EPS Est.
-$190.00
EPS Surpr.
—
Revenue
—
Q2 FY2026
Apr 6, 2026
EPS Actual
-$0.06
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q4 FY2025
Nov 12, 2025
EPS Actual
-$0.04
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q3 FY2025
Aug 15, 2025
EPS Actual
-$0.09
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q2 FY2025
May 19, 2025
EPS Actual
-$2.15
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q2 FY2025
Apr 8, 2025Beat
EPS Actual
-$11.12
EPS Est.
-$98.50
EPS Surpr.
+88.7%
Revenue
—
Q4 FY2024
Nov 14, 2024Beat
EPS Actual
-$36.00
EPS Est.
-$95.00
EPS Surpr.
+62.1%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q1 FY2030 | $-98.50 | $-98.50 | $-98.50 | 1 |
| Q4 FY2029 | $-95.00 | $-95.00 | $-95.00 | 1 |
| Q3 FY2029 | $-185.50 | $-185.50 | $-185.50 | 1 |
| Q2 FY2029 | $-180.00 | $-180.00 | $-180.00 | 1 |
| Q1 FY2029 | $-131.50 | $-131.50 | $-131.50 | 1 |
| Q4 FY2028 | $-134.00 | $-134.00 | $-134.00 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q1 FY2030 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2029 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2029 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2029 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2029 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2028 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| — Q2 FY2026 | Apr 6, 2026 | — | $0.06 | $0.06 | +0.00% |
| — Q4 FY2025 | Nov 12, 2025 | — | $0.07 | $0.07 | +0.00% |
| — Q3 FY2025 | Aug 15, 2025 | — | $0.06 | $0.06 | +5.00% |
| — Q2 FY2025 | May 19, 2025 | — | $0.11 | $0.10 | -11.82% |
| ▲ Q2 FY2025 | Apr 8, 2025 | +88.7% | $0.44 | $0.41 | -6.82% |
| ▲ Q4 FY2024 | Nov 14, 2024 | +62.1% | $32.28 | $33.25 | +3.00% |
| ▲ Q3 FY2024 | Aug 13, 2024 | +81.7% | $29.98 | $29.51 | -1.57% |
| ▲ Q2 FY2024 | Apr 16, 2024 | +8.0% | $109.00 | $102.00 | -6.42% |
Q2 FY2026+0.00%
Report Date
Apr 6, 2026
EPS Beat/Miss
—
Price Before
$0.06
Price After
$0.06
Q4 FY2025+0.00%
Report Date
Nov 12, 2025
EPS Beat/Miss
—
Price Before
$0.07
Price After
$0.07
Q3 FY2025+5.00%
Report Date
Aug 15, 2025
EPS Beat/Miss
—
Price Before
$0.06
Price After
$0.06
Q2 FY2025-11.82%
Report Date
May 19, 2025
EPS Beat/Miss
—
Price Before
$0.11
Price After
$0.10
Q2 FY2025-6.82%
Report Date
Apr 8, 2025
EPS Beat/Miss
+88.7%
Price Before
$0.44
Price After
$0.41
Q4 FY2024+3.00%
Report Date
Nov 14, 2024
EPS Beat/Miss
+62.1%
Price Before
$32.28
Price After
$33.25
Q3 FY2024-1.57%
Report Date
Aug 13, 2024
EPS Beat/Miss
+81.7%
Price Before
$29.98
Price After
$29.51
Q2 FY2024-6.42%
Report Date
Apr 16, 2024
EPS Beat/Miss
+8.0%
Price Before
$109.00
Price After
$102.00
Avg Beat Reaction-2.95%
Beat Rate4 / 8 quarters
Largest Move-11.82% (Q2 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: HEPA ends December
Hepion Pharmaceuticals, Inc. (HEPA) most recently reported earnings on April 6, 2026 for Q2 FY2026, posting EPS of $-0.06 (in line with the analyst consensus of —). HEPA has beaten EPS estimates for 5 consecutive quarters. The next HEPA earnings date is expected around September 1, 2026.
Each quarter, investors track HEPA earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. HEPA revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
HEPA's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
HEPA earnings · 4 questionsHepion Pharmaceuticals, Inc.'s next earnings report is expected around September 1, 2026. HEPA typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; HEPA historically reports after market close (AMC).
HEPA earnings datewhen is HEPA earningsHEPA next earnings datewhen does HEPA report earningsHEPA earnings calendar
▸ Source: FMP · Hepion Pharmaceuticals, Inc. SEC filings · US GAAP · Hepion Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026